New drug combo aims to shrink kidney tumors before surgery

NCT ID NCT07397611

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the drug casdatifan, alone or with zimberelimab, can safely shrink kidney tumors before surgery in people with clear cell renal cell carcinoma. About 32 adults with advanced or high-risk kidney cancer will receive the drugs before their planned nephrectomy. The main goal is to see if the tumor size decreases, while also monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Casdatifan (a HIF-2α inhibitor) and Zimberelimab (an immunotherapy drug)
What this could lead to: If successful, this could show that combining these drugs before surgery helps shrink kidney tumors, potentially leading to better surgical outcomes and a new treatment approach for clear cell renal cell carcinoma.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply to all patients. The drugs may cause side effects, and it's unknown if tumor shrinkage will translate to long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer kidney neoplasm nonpapillary renal cell carcinoma renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER KIDNEY NEOPLASM RENAL CARCINOMA RENAL CELL CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.